45 reports

  • 4.1 ETIOLOGY
  • 12.1 BIBLIOGRAPHY

TUBERCULOSIS AND HIV.

  • Antiviral
  • East Asia
  • Gilead Sciences, Inc.
  • Merck & Co., Inc.
  • ViiV Healthcare Ltd.

The same study revealed that every year, around ##, ## new multidrug-resistant tuberculosis cases were found among one million tuberculosis cases.

  • Antiviral
  • China
  • Gilead Sciences, Inc.
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Chapter V
  • Chapter V

IN 2007, THE GLOBAL FUND TO FIGHT AIDS, TUBERCULOSIS AND MALARIA AWARDED CHINA A FIVE-YEAR GRANT TO STRENGTHEN THE OPERATIONAL SYSTEM OF THE FREE ANTIRETROVIRAL TREATMENT PROGRAMME.

  • Antiviral
  • China
  • Demand
  • Market Size
  • Supply

Tuberculosis and HIV.

  • Antiviral
  • East Asia
  • Japan
  • Forecast
  • UNAIDS

STRENGTH: ## LOW; ## HIGH F.

  • Antiviral
  • Bristol-Myers Squibb Company
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • ViiV Healthcare Ltd.

Periodic Assessment of the Molecular Diagnostic Market for Mycobacterium tuberculosis (MTB) Tests in Germany, 2014 Total number of clinical diagnostic labs by segment: small, medium and large hospitals, independent (private) labs Number of clinical diagnostic molecular labs by segment: smal

  • Antiviral
  • Infectious Disease
  • Molecular Diagnostic
  • Pathology
  • Germany

Periodic Assessment of the Molecular Diagnostic Market for Mycobacterium tuberculosis (MTB) Tests in UK, 2014 Total number of clinical diagnostic labs by segment: small, medium and large hospitals, independent (private) labs Number of clinical diagnostic molecular labs by segment: small, me

  • Antiviral
  • Infectious Disease
  • Molecular Diagnostic
  • Pathology
  • United Kingdom

Periodic Assessment of the Molecular Diagnostic Market for Mycobacterium tuberculosis (MTB) Tests in Italy, 2014 Total number of clinical diagnostic labs by segment: small, medium and large hospitals, independent (private) labs Number of clinical diagnostic molecular labs by segment: small,

  • Antiviral
  • Infectious Disease
  • Molecular Diagnostic
  • Pathology
  • Italy

Periodic Assessment of the Molecular Diagnostic Market for Mycobacterium tuberculosis (MTB) Tests in France, 2014 Total number of clinical diagnostic labs by segment: small, medium and large hospitals, independent (private) labs Number of clinical diagnostic molecular labs by segment: small

  • Antiviral
  • Infectious Disease
  • Molecular Diagnostic
  • Pathology
  • France

Periodic Assessment of the Molecular Diagnostic Market for Mycobacterium tuberculosis (MTB) Tests in Switzerland, 2014 Total number of clinical diagnostic labs by segment: small, medium and large hospitals, independent (private) labs Number of clinical diagnostic molecular labs by segment:

  • Antiviral
  • Infectious Disease
  • Molecular Diagnostic
  • Pathology
  • Switzerland

Periodic Assessment of the Molecular Diagnostic Market for Mycobacterium tuberculosis (MTB) Tests in Sweden, 2014 Total number of clinical diagnostic labs by segment: small, medium and large hospitals, independent (private) labs Number of clinical diagnostic molecular labs by segment: small

  • Antiviral
  • Infectious Disease
  • Molecular Diagnostic
  • Pathology
  • Sweden

Periodic Assessment of the Molecular Diagnostic Market for Mycobacterium tuberculosis (MTB) Tests in Spain, 2014 Total number of clinical diagnostic labs by segment: small, medium and large hospitals, independent (private) labs Number of clinical diagnostic molecular labs by segment: small,

  • Antiviral
  • Infectious Disease
  • Molecular Diagnostic
  • Pathology
  • Spain

Periodic Assessment of the Molecular Diagnostic Market for Mycobacterium tuberculosis (MTB) Tests in The Netherlands, 2014 Total number of clinical diagnostic labs by segment: small, medium and large hospitals, independent (private) labs Number of clinical diagnostic molecular labs by segme

  • Antiviral
  • Infectious Disease
  • Molecular Diagnostic
  • Pathology
  • Netherlands

Source: GlobalData, Pharma Intelligence Center [Accessed February 2018] Pre-Registration ## ## - - ## - Filing rejected/ Withdrawn ## - - ## - - Phase III ## ## - - ## ## Phase II ## - - - ## ## Phase I ## - ## - ## ## Phase ## - - - - - ## IND/ CTA Fil

  • Antiviral
  • United States
  • Gilead Sciences, Inc.
  • Janssen Biotech, Inc.
  • ViiV Healthcare Ltd.
  • RENAME

These include malaria, tuberculosis, cholera, meningitis and a number of sexually-transmitted infections.

  • Antiviral
  • Pharmaceutical
  • Brazil
  • Demand
  • GlaxoSmithKline plc
  • 17.1 COMPETITIVE SCENARIO

The CDC reported that ##, ## people had tuberculosis and ##, ## individuals had Salmonella and Lyme disease in the country in 2011.

  • Antiviral
  • United States
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc

HIV

4546 5000 3864

Kim AY, Chung RT (2009) Coinfection With HIV-## and HCV-A One-Two Punch.

  • Antiviral
  • Europe
  • European Union
  • North America
  • United States

THE APPROACH OF USING COMBINATION THERAPY WAS INITIALLY ADOPTED TO TREAT TUBERCULOSIS AND OTHER INFECTIOUS DISEASES.

  • Antiviral
  • North America
  • United States
  • Incyte Corporation
  • Merck & Co., Inc.
  • CC-11050 - DRUG PROFILE

" We think we can do it with one shot. "

  • Antiviral
  • Infectious Disease
  • United States
  • World
  • Product Initiative

Tuberculosis ## West Nile Virus Infection ## Zika Virus Infection ## Chikungunya Virus Infection ## Chronic Traumatic Encephalopathy ## Dengue Virus Infection ## Ebola Virus Infection ## Hepatitis C Infection ## Breast Cancer

  • Antiviral
  • United States
  • Company
  • Product Initiative
  • Aethlon Medical, Inc.
  • LICENSING AGREEMENTS
  • Chimerix Raises USD122 Million in Public Offering of Shares

It also develops active compounds against influenza A and B, malaria, brincidofovir for smallpox, brincidofovir and adenovirus, dengue virus and tuberculosis.

  • Antiviral
  • Pharmaceutical
  • United States
  • Corporate Finance
  • Chimerix, Inc.
  • SMALL MOLECULES FOR TUBERCULOSIS - DRUG PROFILE
  • SMALL MOLECULES 4 FOR ONCOLOGY - DRUG PROFILE

Biomar Microbial Technologies - Product Pipeline Review - 2016 Summary Global Markets Direct’s, ‘Biomar Microbial Technologies - Product Pipeline Review - 2016’, provides an overview of the Biomar Microbial Technologies’s pharmaceutical research and development focus. The report provides comprehensive information...

  • Antiviral
  • Oncology
  • Therapy
  • World
  • Product Initiative
  • 5. ALL THE TRIALS INCLUDED ARE UNIQUE TRIALS.

Hoffmann-La Roche Ltd ## ## ## ## ## ## ## ## Bristol-Myers Squibb Company ## ## ## ## ## ## ## ## Merck & Co Inc ## ## ## ## ## ## ## ## Sanofi ## ## ## ## ## ## ## ## Novartis AG ## ## ## ## ## ## ## ## Bukwang Pharm Co Ltd ## ## ## ## ## ##

  • Antiviral
  • Hepatitis
  • Infectious Disease
  • World
  • GlaxoSmithKline plc

The microbiology tests detect pathogens including tuberculosis and fungi, and bacteria such as MRSA.

  • Anesthetics
  • Antiviral
  • Diagnostics
  • In Vitro Diagnostic Reagent
  • Roche Group
  • CHIMERIX ENTERS INTO LICENSING AGREEMENT WITH CONTRAVIR PHARMA FOR CMX157

It also develops active compounds against influenza A and B, malaria, brincidofovir for smallpox, brincidofovir and adenovirus, dengue virus and tuberculosis.

  • Antiviral
  • Hepatitis
  • United States
  • Corporate Finance
  • ContraVir Pharmaceuticals, Inc.

Tamiflu (oseltamivir) and Alferon were tested in A## cells for antiviral activity in vitro against the wild-type (wt) human A(H##N##) isolate A/ Anhui/ ##/ 2013 (wt Anhui ##) and a patient isolate (A/ Shanghai/ ##/ 2013 (NA-##K; Shanghai ##- NA

  • Antiviral
  • United States
  • World
  • Product Initiative
  • Hemispherx Biopharma, Inc.

The institute' s research areas include infectious diseases such as tuberculosis and influenza, HIV/ AIDS, biodefense; and immune-mediated diseases including asthma and allergy.

  • Antiviral
  • Healthcare
  • Israel
  • United States
  • BiondVax Pharmaceuticals Ltd.
  • Discovery/Preclinical Trial Details
  • LALISTAT - DRUG PROFILE

Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline Review, H2 2017 Summary Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline Review, H2 2017, provides an overview of the Human Immunodeficiency...

  • Antiviral
  • HIV AIDS
  • Pathology
  • Vaccine
  • Merck & Co., Inc.

The period saw the launch of the Genedrive®tuberculosis (TB) and associated antibiotic resistance test in India.

  • Antiviral
  • Clinical Trial
  • DNA
  • Hepatitis
  • GlobalData's company
  • SMALLPOX - PIPELINE BY CHIMERIX INC, H1 2018
  • SMALLPOX - PIPELINE BY CEL-SCI CORP, H1 2018

It also develops active compounds against influenza A and B, malaria, brincidofovir for smallpox, brincidofovir and adenovirus, dengue virus and tuberculosis.

  • Antiviral
  • Therapy
  • United States
  • Product Initiative
  • Chimerix, Inc.